These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30198549)

  • 1. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
    Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
    Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
    Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Amaador K; Kersten MJ; Visser O; Brink M; Posthuma EFM; Minnema MC; Vos JMI; Dinmohamed AG
    Br J Haematol; 2022 Feb; 196(3):660-669. PubMed ID: 34605017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Brandefors L; Sander B; Lundqvist K; Kimby E
    Br J Haematol; 2022 Mar; 196(6):1362-1368. PubMed ID: 34959252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
    Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
    Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.
    Brandefors L; Kimby E; Lundqvist K; Melin B; Lindh J
    Acta Oncol; 2016; 55(1):91-8. PubMed ID: 26559865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Hultcrantz M; Pfeiffer RM; Björkholm M; Goldin LR; Turesson I; Schulman S; Landgren O; Kristinsson SY
    J Thromb Haemost; 2014 Nov; 12(11):1816-21. PubMed ID: 25196979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
    Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
    Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
    Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
    Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
    Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Slawik HR; Bückner U; Otremba B; Sauer A; Zahn MO; Wetzel N; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2020 Aug; 38(3):344-352. PubMed ID: 32383192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N
    J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
    Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
    Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003.
    Iwanaga M; Chiang CJ; Soda M; Lai MS; Yang YW; Miyazaki Y; Matsuo K; Matsuda T; Sobue T
    Int J Cancer; 2014 Jan; 134(1):174-80. PubMed ID: 23784625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Waldenström macroglobulinemia: Japanese perception].
    Sekiguchi N
    Rinsho Ketsueki; 2019; 60(8):988-997. PubMed ID: 31484900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
    Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
    Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.